Dergiler / Acta Medica / 2022 / Cilt: 53 - Sayı: 2

Repetitive Transcranial Magnetic Stimulation in a Group of Treament-Resistant Obsessive-Compulsive Disorder Patients: A Descriptive Study

Sayfa
114–122
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Results: Mean Y-BOCS scores decreased significantly across week 0 and the 3rd week (t(26)=10.59, p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: This study aims to investigate the effects of repetitive transcranial magnetic stimulation (rTMS) treatment in a group of treatment-resistant obsessive-compulsive disorder (OCD) patients and to examine the relationship between various sociodemographic and clinical variables and treatment response.
📊
Temel Bulgular & Veri:Materials and Methods: Data including The Yale–Brown Obsessive Compulsive Scale (Y-BOCS) scores and various clinical and sociodemographic characteristics of 27 treatment-resistant OCD patients who received 30 sessions of low-frequency rTMS (LF-rTMS) treatment on the left dorsolateral prefrontal cortex (DLPFC) were analyzed.
💡
Sonuç & Katkı:Results: Mean Y-BOCS scores decreased significantly across week 0 and the 3rd week (t(26)=10.59, p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: This study aims to investigate the effects of repetitive transcranial magnetic stimulation (rTMS) treatment in a group of treatment-resistant obsessive-compulsive disorder (OCD) patients and to examine the relationship between various sociodemographic and clinical variables and treatment response. Materials and Methods: Data including The Yale–Brown Obsessive Compulsive Scale (Y-BOCS) scores and various clinical and sociodemographic characteristics of 27 treatment-resistant OCD patients who received 30 sessions of low-frequency rTMS (LF-rTMS) treatment on the left dorsolateral prefrontal cortex (DLPFC) were analyzed. Results: Mean Y-BOCS scores decreased significantly across week 0 and the 3rd week (t(26)=10.59, p

🔖

Bu Makaleye Atıf Yap

CİNEMRE, B., TOPÇUOĞLU, M., ERDOĞAN, A., NABİYEVA, N. (2022). Repetitive Transcranial Magnetic Stimulation in a Group of Treament-Resistant Obsessive-Compulsive Disorder Patients: A Descriptive Study. Acta Medica, Cilt: 53 - Sayı: 2, 114–122. https://ajindex.com/articles/427512

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (7)

  1. Zhou DD, Wang W, Wang GM, et al. An updated metaanalysis: Short-term therapeutic effects of repeated transcranial magnetic stimulation in treating obsessivecompulsive disorder. J Affect Disord 2017; 215:187-196.
  2. Van Ameringen M, Patterson B, Simpson W. DSM-5 obsessive-compulsive and related disorders: clinical implications of new criteria. Depress Anxiety 2014; 31: 487-93.
  3. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessivecompulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008; 9(4):248-312. https:// doi.org/10.1080/15622970802465807 [4] Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, posttraumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 2014; 28(5):403-439. https://doi. org/10.1177/0269881114525674 [5] Stein DJ, Koen N, Fineberg N, et al. A 2012 evidencebased algorithm for the pharmacotherapy for obsessivecompulsive disorder. Curr Psychiatry Rep. 2012;14(3):211- 9.
  4. Jaafari N, Rachid F, Rotge JY, et al. Safety and efficacy of repetitive transcranial magnetic stimulation in the treatment of obsessive-compulsive disorder: a review. World J Biol Psychiatry 2012; 13(3):164-177. https://doi.or g/10.3109/15622975.2011.575177 [7] Tolin D, Abramowitz J, Diefenbach G. Defining response in clinical trials for obsessive compulsive disorder: A signal detection analysis of the Yale-Brown Obsessive Compulsive Scale. J Clin Psychiatry. 2005;66(12):1549- 1557.
  5. Walsh KH, McDougle CJ. Pharmacological augmentation strategies for treatment-resistant obsessive-compulsive disorder. Expert Opin Pharmacother 2004;5:2059-67.
  6. Pallanti S, Hollander E, Goodman WK. A qualitative analysis of non-response: Management of treatmentrefractory obsessive-compulsive disorder. J Clin Psychiatry 2004;65:6-10.
  7. Pallanti S, Hollander E, Bienstock C, et al. Treatment nonresponse in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol. 2002;5(2):181- 91. https://doi.org/10.1017/S146114570